MagicMed Sets Out to Help Partners Develop Pharma-Grade Psychedelics


Ryan Allway

July 22nd, 2020

App, Exclusive, Psychedelics, Top Story


The psychedelics industry is projected to grow at a 16.3% compound annual growth rate to reach $6.85 billion, according to Data Bridge Market Research, driven by the increasing prevalence of mental health disorders and a growing acceptance of psychedelic drugs for the treatment of these diseases. With more than 15 publicly traded companies, investors have a growing number of options targeting the space.  

MagicMed Industries is taking one of the most innovative approaches, developing derivative psychedelic molecules using its proprietary scientific tools. These derivatives will form a library of sorts—called the Psybrary™—that partners can search, select, test and use as building blocks for their own products.

Let’s take a closer look at the company’s unique business model and why the management team is uniquely qualified to execute on those plans. 

Building Mainstream Molecules

MagicMed works with pharmaceutical or consumer product companies looking to accelerate their psychedelic product lines. While natural psychedelic molecules cannot be patented as molecular composition, new molecular derivative compositions are patentable. The company’s Psybrary™ represents a collection of these derivatives that its partners can license to create a competitive edge.

In the pharmaceutical space, the company seeks to create improved molecules that work best for mainstream pharmaceuticals. The team is focused on formulating the right molecules, building a patent portfolio around them, and licensing the molecules out to large pharmaceutical companies that can push them through clinical trials, manufacture, and deliver them to patients at scale.

Click here to receive an investor presentation and corporate updates 

The business model is attractive for investors because the company works with numerous partners—diversifying risk— and generates revenue with very little cost. Partners pay fixed and variable costs for drug development plus milestone payments, enabling the company to quickly reach positive cash flow. Long-term royalties then create larger blue-sky opportunities at attractive margins. 

Experienced Board & Management

MagicMed’s management team has a wealth of experience with both cannabinoids and opioids—two other molecules that affect the human brain. Like cannabinoids and opioids, psychedelics impact receptors in the brain that have different effects on people. The management team has now turned its focus and extensive expertise to the psychedelics market. 

Dr. Joseph Tucker built several publicly traded biotechnology companies before becoming MagicMed’s Chief Executive Officer. While Dr. Tucker is focused on partnerships, capital raising and the pursuit of a successful exit strategy, Chief Operating Officer Dr. Jillian Hagel is leveraging her experience as COO and VP at several biotech companies to lead the science team in reaching partner milestones. 

The company’s science team is led by Chief Science Officer Dr. Peter Facchini, who has held a similar role at many other public and private biotech firms. As a recognized expert in developing new molecular derivatives, Dr. Facchini has published more than 160 scientific papers and holds 20 patents in the field. His singular goal is to create patented psychedelic derivatives to bring to market.

Click the image to view an interview with CEO, Dr. Joseph Tucker

Click here to receive an investor presentation and corporate updates 

Looking Ahead

MagicMed Industries is uniquely positioned to capitalize on the nascent psychedelics industry with its innovative business model and capable management team. As of July, the company has raised $600,000 and plans on a public listing during the first or second quarter of 2021. Management will use the proceeds from a public listing to further increase partners and potentially diversify into consumer goods. 

If you’re interested in becoming an early-stage investor, download the company’s investor presentation and sign up to receive more information.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading